Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.65 |
| ▸ | NPBWR1 | P48145 | 7/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 8/20 | 0.52 |
| ▸ | GLP1R | P43220 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974005 | 0.97 | PRMT1 (0.63) | PRMT1NPBWR1IL23RGLP1ROPRM1 | |
| SCHEMBL30974132 | 0.94 | PRMT1 (0.64) | PRMT1NPBWR1IL23RGLP1R | |
| SCHEMBL30973994 | 0.91 | PRMT1 (0.58) | PRMT1NPBWR1IL23ROPRM1OPRD1 | |
| SCHEMBL30974062 | 0.91 | PRMT1 (0.57) | PRMT1NPBWR1IL23ROPRM1OPRD1 | |
| SCHEMBL30974279 | 0.91 | PRMT1 (0.55) | PRMT1NPBWR1IL23ROPRM1OPRD1 | |
| SCHEMBL11407920 | 0.88 | IL23R (0.59) | PRMT1IL23R | |
| SCHEMBL11407870 | 0.88 | IL23R (0.59) | PRMT1IL23R | |
| SCHEMBL30116700 | 0.87 | PRMT1 (0.61) | PRMT1NPBWR1GLP1R | |
| SCHEMBL30566944 | 0.87 | IL23R (0.57) | PRMT1IL23RGLP1ROPRM1OPRD1 | |
| SCHEMBL28081219 | 0.87 | GLP1R (0.61) | PRMT1NPBWR1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | disclosed |